keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28330497/atopic-dermatitis-anti-ige-paediatric-trial-adapt-the-role-of-anti-ige-in-severe-paediatric-eczema-study-protocol-for-a-randomised-controlled-trial
#1
Susan Chan, Victoria Cornelius, Tao Chen, Suzana Radulovic, Mandy Wan, Rahi Jahan, Gideon Lack
BACKGROUND: The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects. There is increasing in vitro and murine-model evidence for the role of IgE in the immunopathogenesis of atopic eczema. The aim of the study is to assess whether anti-IgE treatment (omalizumab) improves eczema, compared to placebo...
March 22, 2017: Trials
https://www.readbyqxmd.com/read/28319473/precision-medicine-in-asthma-the-role-of-bronchial-thermoplasty
#2
Amber J Oberle, Praveen Mathur
PURPOSE OF REVIEW: The inflammatory makeup of severe asthma is heterogeneous. Identification of the predominant cellular endotype via biomarkers can aid in the selection of more advanced therapies. This review is clinically focused on how to use these biomarkers to help select between biologic agents and/or bronchial thermoplasty. RECENT FINDINGS: Several Th2 biomarkers exist for the detection of eosinophilic disease; however, the best biomarker for clinical practice is debatable depending upon local resources...
March 17, 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/28314658/management-of-chronic-inducible-urticaria-according-to-the-guidelines-a-prospective-controlled-study
#3
Emek Kocatürk, Pelin Kuteyla Can, Pırıl Etikan Akbas, Mehmet Copur, Ece Nur Degirmentepe, Kübra Kızıltac, Ralfi Singer
BACKGROUND: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. OBJECTIVE: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. METHODS: This prospective parallel group controlled study included 70 CIndU and 66 CSU patients...
March 1, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28303277/basophil-fc%C3%AE%C2%B5ri-expression-in-chronic-spontaneous-urticaria-a-poten-tial-immunological-predictor-of-response-to-omalizumab-therapy
#4
Gustavo Deza, Marta Bertolín-Colilla, Ramon M Pujol, Laia Curto-Barredo, Dulce Soto, Maribel García, Pilar Hernández, Ramon Gimeno, Ana M Giménez-Arnau
Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment...
March 17, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28303134/bronchial-epithelial-cells-from-asthmatic-patients-display-less-functional-hla-g-isoform-expression
#5
Federico Carlini, Christophe Picard, Céline Garulli, David Piquemal, Pierre Roubertoux, Jacques Chiaroni, Pascal Chanez, Delphine Gras, Julie Di Cristofaro
Not all asthmatic patients adequately respond to current available treatments, such as inhaled corticosteroids or omalizumab(®). New treatments will aim to target the bronchial epithelium-immune response interaction using different pathways. HLA-G is involved in immunomodulation and may promote epithelial cell differentiation and proliferation. HLA-G protein has several isoforms generated by alternative splicing that might have differential functionalities. HLA-G protein expression and genetic polymorphisms have been reported to be associated with asthma...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28302544/can-the-response-to-omalizumab-be-influenced-by-treatment-duration-a-real-life-study
#6
Bruno Sposato, Marco Scalese, Manuela Latorre, Federica Novelli, Nicola Scichilone, Manlio Milanese, Carmela Olivieri, Antonio Perrella, Pierluigi Paggiaro
OBJECTIVE: It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. METHODS: 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: <12, between 12 and 24, between 24 and 60 and >60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared...
March 13, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28295198/analysis-of-disease-activity-categories-in-chronic-spontaneous-idiopathic-urticaria
#7
D Stull, D McBride, H Tian, A Gimenez Arnau, M Maurer, A Marsland, M-M Balp, S Khalil, C Grattan
BACKGROUND: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score-here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD )-measures severity from 0 to 42. Insufficient evidence exists whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. OBJECTIVE: To evaluate and compare categorical UAS7TD scores with selected measures of disease-related quality of life and impact...
March 13, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28294590/successful-omalizumab-treatment-in-hiv-positive-patient-with-chronic-spontaneous-urticaria-a-case-report
#8
E Iemoli, F Niero, L Borgonovo, M V Cossu, S Piconi
We described a case of a 56 year old homosexual HIV positive man who presented a history of CSU since one year (2012). All the allergologic, immunologic and microbiologic tests to evaluate the pathogenesis of wheals resulted negative. Therefore in June 2015 we decided to start therapy with Omalizumab while the patient kept on effective antiretroviral therapy with 310 cells/mm3 TCD4 counts and undetectable HIV viremia. After two monthly subcutaneuous injection of 150 mg of Omalizumab the patient had no more urticarial symptoms...
March 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28294420/chronic-urticaria-in-the-real-life-clinical-practice-setting-in-sweden-norway-and-denmark-baseline-results-from-the-non-interventional-multicentre-aware-study
#9
S F Thomsen, E C Pritzier, C D Anderson, N Vaugelade-Baust, R Dodge, A-K Dahlborn, C Vestergaard
BACKGROUND: Chronic urticaria (CU) is characterised by the recurrence of itchy hives and/or angioedema for more than six weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease, and clinical resource usage of H1-antihistamine refractory CU patients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28293414/galectin-3-an-early-predictive-biomarker-of-modulation-of-airway-remodeling-in-patients-with-severe-asthma-treated-with-omalizumab-for-36%C3%A2-months
#10
Anna Maria Riccio, Pierluigi Mauri, Laura De Ferrari, Rossana Rossi, Dario Di Silvestre, Louise Benazzi, Alessandra Chiappori, Roberto Walter Dal Negro, Claudio Micheletto, Giorgio Walter Canonica
BACKGROUND: Bronchial asthma is a heterogeneous disease characterized by three cardinal features: chronic inflammation, variable airflow obstruction, and airway hyperresponsiveness. Asthma has traditionally been defined using nonspecific clinical and physiologic variables that encompass multiple phenotypes and are treated with nonspecific anti-inflammatory therapies. Based on the modulation of airway remodeling after 12 months of anti-immunoglobulin E (IgE) treatment, we identified two phenotypes (omalizumab responder, OR; and non-omalizumab responder, NOR) and performed morphometric analysis of bronchial biopsy specimens...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28287273/novel-monoclonal-treatments-in-severe-asthma
#11
Howraman Meteran, Hanieh Meteran, Celeste Porsbjerg, Vibeke Backer
AIM: To provide a general overview of the current biological treatments and discuss their potential anti-asthmatic effects. DATA SOURCES: We reviewed articles in PubMed found using the search words "Asthma/therapy AND antibodies, monoclonal/therapeutic use AND cytokines." STUDY SELECTIONS: Only articles published in English since 2000 were considered. The search identified 29 studies; 8 additional studies were found by hand search, generating 37 studies...
March 13, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28284319/longterm-clinical-outcomes-of-omalizumab-therapy-in-severe-allergic-asthma-study-of-efficacy-and-safety
#12
Adel H Mansur, Sapna Srivastava, Verity Mitchell, Julie Sullivan, Ismail Kasujee
Omalizumab has been shown to be an effective add-on therapy for patients with uncontrolled severe persistent allergic asthma. There has been a steady accumulation of evidence on the long-term effectiveness of omalizumab; however, data on real-life outcomes beyond one year of treatment is limited. In this study, we report on long-term outcomes of omalizumab treatment. We collected data from our severe asthma registry on hospitalisations, exacerbations, corticosteroid sparing, asthma control, lung function, biomarkers and side effects, to determine if the benefit was sustained and treatment was safe on the long term...
March 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28283854/management-of-the-asthma-copd-overlap-syndrome-acos-a-review-of-the-evidence
#13
REVIEW
Kristin L Hines, R Stokes Peebles
PURPOSE OF REVIEW: Examine the definition of the asthma-COPD overlap syndrome (ACOS) and current treatment strategies. RECENT FINDINGS: Patients with the ACOS have a lower quality of life and suffer from more complications than those affected by either disease alone. Diagnosis of ACOS is difficult because of the clinical similarities between the two diseases and the various phenotypes that comprise the syndrome. Defining treatment strategies for ACOS has been challenging because many clinical trials for asthma therapy have purposefully excluded patients with features of COPD, and COPD clinical trials have not included patients who might have an asthmatic component to their disease...
March 2017: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/28283278/sex-differences-in-the-efficacy-safety-and-tolerability-of-omalizumab-after-1-year-in-maltese-patients-with-asthma
#14
Caroline Gouder, Rachelle Asciak, Stephen Montefort
No abstract text is available yet for this article.
March 7, 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28281440/monoclonal-antibody-therapy-in-sinonasal-disease
#15
S E Chiarella, H Sy, A T Peters
Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. POPULATION: CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agentsare emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP...
March 9, 2017: American Journal of Rhinology & Allergy
https://www.readbyqxmd.com/read/28279664/combination-omalizumab-and-mepolizumab-therapy-for-refractory-allergic-bronchopulmonary-aspergillosis
#16
Matthew C Altman, Jake Lenington, Steve Bronson, Andrew G Ayars
No abstract text is available yet for this article.
March 6, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28279283/correction-to-figures%C3%A2-in-omalizumab-treatment-response-in-a-population-with-severe-allergic-asthma-and-overlapping-copd
#17
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Chest
https://www.readbyqxmd.com/read/28274526/efficacy-of-long-term-omalizumab-therapy-in-patients-with-severe-asthma
#18
Junko Saji, Takahito Yamamoto, Motonaka Arai, Masamichi Mineshita, Teruomi Miyazawa
BACKGROUND: The efficacy of omalizumab, an anti-immunoglobulin E (IgE) antibody, has been studied in patients with severe bronchial asthma. We conducted a study to evaluate, on the basis of both objective and subjective measures, the efficacy of omalizumab as a long-term therapy in patients with severe and persistent asthma. METHODS: Omalizumab was administered subcutaneously every two or four weeks. The results of pulmonary function tests, Asthma Control Test (ACT) and Asthma Health Questionnaire (AHQ)-33 scores, the dosage of methylprednisolone during the 12-month treatment period, and the number of emergency visits prior to the start of treatment with omalizumab were compared in patients pre- and post-treatment with omalizumab...
March 2017: Respiratory Investigation
https://www.readbyqxmd.com/read/28273376/omalizumab-does-not-improve-skin-lesions-in-a-patient-with-hypocomplementemic-urticarial-vasculitis-syndrome
#19
S Aurich, J C Simon, R Treudler
Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare immune complex- mediated disease being characterized by persistent urticarial lesions, hypocomplementemia and possible organ involvement [1]. Therapy of HUVS is reported to be challenging [2]. We report on a 36 year old non atopic female who first presented in our university allergy centre with 18 months history of recurrent urticarial flares. This article is protected by copyright. All rights reserved.
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28264494/omalizumab-is-equally-effective-in-persistent-allergic-oral-corticosteroid-dependent-asthma-caused-by-either-seasonal-or-perennial-allergens-a-pilot-study
#20
Christian Domingo, Xavier Pomares, Albert Navarro, Núria Rudi, Ana Sogo, Ignacio Dávila, Rosa M Mirapeix
Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table. For each patient with asthma due to seasonal allergens, we recruited the next two consecutive patients with asthma due to perennial allergens. The dose of oral methyl prednisolone was tapered at a rate of 2 mg every two weeks after the start of treatment with omalizumab depending on tolerance...
February 28, 2017: International Journal of Molecular Sciences
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"